<SEC-DOCUMENT>0001078782-13-001301.txt : 20130703
<SEC-HEADER>0001078782-13-001301.hdr.sgml : 20130703
<ACCEPTANCE-DATETIME>20130702173444
ACCESSION NUMBER:		0001078782-13-001301
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130701
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130703
DATE AS OF CHANGE:		20130702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OphthaliX, Inc.
		CENTRAL INDEX KEY:			0001218683
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880445169
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52545
		FILM NUMBER:		13950010

	BUSINESS ADDRESS:	
		STREET 1:		1656 REUNION AVENUE
		STREET 2:		SUITE 250
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		801-446-8802

	MAIL ADDRESS:	
		STREET 1:		1656 REUNION AVENUE
		STREET 2:		SUITE 250
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DENALI CONCRETE MANAGEMENT INC
		DATE OF NAME CHANGE:	20030213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k070213_8k.htm
<DESCRIPTION>FORM 8-K CURRENT REPORT
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>FORM 8-K Current Report</TITLE>
<META NAME="author" CONTENT="Eric Chess Bronk">
<META NAME="date" CONTENT="07/02/2013">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:624px"><P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B>UNITED STATES</B></P>
<P style="margin:0px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>WASHINGTON, D.C. &nbsp;20549</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center>CURRENT REPORT</P>
<P style="margin:0px" align=center>PURSUANT TO SECTION 13 OR 15(d) OF THE</P>
<P style="margin:0px" align=center>SECURITIES EXCHANGE ACT OF 1934</P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center>Date of report (Date of earliest event reported) &nbsp;&nbsp;<B>July 1, 2013</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:14pt" align=center><B>OphthaliX Inc.</B></P>
<P style="margin:0px" align=center>(Exact Name of Registrant as Specified in its Charter)</P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=199.2 /><TD width=212.8 /><TD width=193.6 /></TR>
<TR><TD style="margin-top:0px" valign=top width=199.2><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD style="margin-top:0px" valign=top width=212.8><P style="margin:0px" align=center><B>000-52545</B></P>
</TD><TD style="margin-top:0px" valign=top width=193.6><P style="margin:0px" align=center><B>88-0445169</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=199.2><P style="margin:0px" align=center>(State or Other Jurisdiction </P>
<P style="margin:0px" align=center>of Incorporation)</P>
</TD><TD style="margin-top:0px" valign=top width=212.8><P style="margin:0px" align=center>(Commission File Number)</P>
</TD><TD style="margin-top:0px" valign=top width=193.6><P style="margin:0px" align=center>(IRS Employer </P>
<P style="margin:0px" align=center>Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=271.2 /><TD width=114 /></TR>
<TR><TD style="margin-top:0px" valign=top width=271.2><P style="margin:0px" align=center><B>10 Bareket Street, Petach Tikva, Israel</B></P>
</TD><TD style="margin-top:0px" valign=top width=114><P style="margin:0px" align=center><B>4951778</B></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=271.2><P style="margin:0px" align=center>(Address of Principal Executive Offices)</P>
</TD><TD style="margin-top:0px" valign=top width=114><P style="margin:0px" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center>Registrant&#146;s telephone number, including area code: &nbsp;<B>+(972) 3-9241114</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=justify>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:48px; float:left">&nbsp;<FONT style="margin-bottom:1.333px; padding-top:1.333px; font-size:6pt; border:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT style="font-size:6pt; color:#FFFFFF">.</FONT></P>
<P style="margin:0px; text-indent:-2px">Written communications pursuant to Rule 425 under the Securities Act</P>
<P style="margin:0px; clear:left"><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:48px; float:left">&nbsp;<FONT style="margin-bottom:1.333px; padding-top:1.333px; font-size:6pt; border:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT style="font-size:6pt; color:#FFFFFF">.</FONT></P>
<P style="margin:0px; text-indent:-2px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act</P>
<P style="margin:0px; clear:left"><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:48px; float:left">&nbsp;<FONT style="margin-bottom:1.333px; padding-top:1.333px; font-size:6pt; border:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT style="font-size:6pt; color:#FFFFFF">.</FONT></P>
<P style="margin:0px; padding-left:48px; text-indent:-2px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act</P>
<P style="margin:0px; clear:left"><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:48px; float:left">&nbsp;<FONT style="margin-bottom:1.333px; padding-top:1.333px; font-size:6pt; border:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT style="font-size:6pt; color:#FFFFFF">.</FONT></P>
<P style="margin:0px; padding-left:48px; text-indent:-2px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act</P>
<P style="margin:0px; clear:left" align=justify><BR></P>
<P style="margin:0px" align=justify><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; page-break-before:always" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:96px; float:left"><B>Item 1.01</B></P>
<P style="margin:0px; text-indent:-2px" align=justify><B>Entry into a Material Definitive Agreement.</B></P>
<P style="margin:0px; clear:left" align=justify><BR></P>
<P style="margin:0px" align=justify>The disclosure set forth in Item 5.02 of this Current Report on Form 8-K is incorporated by reference in this Item 1.01.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:96px; float:left"><B>Item 3.02</B></P>
<P style="margin:0px; text-indent:-2px" align=justify><B>Unregistered Sales of Equity Securities.</B></P>
<P style="margin:0px; clear:left" align=justify><BR></P>
<P style="margin:0px" align=justify>The disclosure set forth in Item 5.02 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:96px; float:left"><B>Item 5.02</B></P>
<P style="margin:0px; padding-left:96px; text-indent:-2px" align=justify><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>
<P style="margin:0px; clear:left" align=justify><BR></P>
<P style="margin:0px" align=justify>On July 1, 2013, the number of directors of OphthaliX Inc. (the &#147;<B>Company</B>&#148;) was increased to five persons and Dr. Michael Belkin was appointed as a director to fill the vacancy created by the increase in the number of directors. &nbsp;In connection with the appointment of Dr. Belkin, the Company entered into an agreement (the &#147;<B>Agreement</B>&#148;) to pay director fees for attendance at meetings of the Board of Directors or any committee of the Board, a copy of which is attached as an exhibit to this report. &nbsp;Dr. Belkin will receive US$2,000 for attendance in person at meetings of the Board, US$750 for attendance by telephone meetings of the Board, and US$750 for attendance at each meeting of any committee of the Board. &nbsp;The Agreement prohibits Dr. Belkin from employment or connection with, or holding any office in, any business or undertaking which competes with any business of the Company or is a customer or supplier of the Company. &nbsp;Management has not determined what, if any, committees to which Dr. Belikin may be appointed.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>In addition, the Company granted Dr. Belkin ten-year options to purchase 235,000 common shares of the Company at $1.475 per share (the &#147;<B>Options</B>&#148;). &nbsp;The Options will vest as follows: &nbsp;19,583 on September 30, 2013 and 1/12<SUP>th</SUP> of the remaining shares shall vest 1/12<SUP>th</SUP> on the last day of each calendar quarter thereafter so long as Dr. Belkin shall remain a director. &nbsp;The Options were granted under the Company&#146;s 2012 Stock Incentive Plan, as amended. &nbsp;The Options were granted without registration under the Securities Act by reason of the exemption from registration afforded by the provisions of Section 4(a)(5) and/or Section 4(a)(2) thereof, and Rule 506 promulgated thereunder, as a transaction by an issuer not involving any public offering. &nbsp;The recipient of the Options was an accredited investor as defined in Rule 501(a) of Regulation D promulgated by the SEC. &nbsp;The securities issued in this transaction were not registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>Except as disclosed herein, there have been no transactions, since the beginning of the Company&#146;s last fiscal year, or any currently proposed transaction, in which the Company was or is to be a participant and in which Dr. Belkin had or will have a direct or indirect material interest.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>A press release announcing the appointment of Dr. Belkin is included as an exhibit to this report.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:96px; float:left"><B>Item 9.01</B></P>
<P style="margin:0px; text-indent:-2px" align=justify><B>Financial Statements and Exhibits.</B></P>
<P style="margin:0px; clear:left" align=justify><BR></P>
<P style="margin:0px" align=justify>(d) Exhibits.</P>
<P style="margin:0px" align=justify><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=84 /><TD width=24 /><TD width=468 /></TR>
<TR><TD style="margin-top:0px" valign=top width=84><P style="margin:0px" align=justify><U>Exhibit No.</U></P>
</TD><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=468><P style="margin:0px" align=justify><U>Description</U></P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=84><P style="margin:0px" align=justify>99.1</P>
</TD><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=468><P style="margin:0px" align=justify>Press Release dated July 2, 2013</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR>
<BR></P>
<P style="margin:0px" align=center>2</P>
<P style="margin:0px"><BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; page-break-before:always" align=justify><BR></P>
<P style="margin:0px" align=center><B>SIGNATURES</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; padding-left:336px" align=justify><B>OphthaliX Inc.</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;July 2, 2013</P>
<P style="margin:0px; padding-left:336px; text-indent:-2px" align=justify>By: <I><U>/s/ Barak Singer</U></I></P>
<P style="margin:0px; padding-left:336px; clear:left" align=justify>Barak Singer, Chief Executive Officer</P>
<P style="margin:0px" align=justify><BR>
<BR></P>
<P style="margin:0px" align=center>3</P>
<P style="margin:0px"><BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: A7CBAD3A -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k070213_ex99z1.htm
<DESCRIPTION>EXHIBIT 99.1 PRESS RELEASE
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Exhibit 99.1 Press Release</TITLE>
<META NAME="author" CONTENT="Barak Singer">
<META NAME="date" CONTENT="07/02/2013">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:624px"><P style="margin-top:0px; margin-bottom:12.2px"><BR></P>
<P style="margin-top:0px; margin-bottom:12.2px"><BR></P>
<P style="margin:0px"><img src="f8k070213_ex99z1001.jpg" alt="[f8k070213_ex99z1001.jpg]" align=middle height=54.667 width=239.533></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B>OphthaliX Appoints Dr. Michael Belkin</B> <B>to its Board of Directors &nbsp;</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>Petach Tikva, Israel, July 2, 2013 / OphthaliX, Inc. (OTC BB: OPLI), is pleased to announce the appointment of Dr. Michael Belkin to the Company&#146;s Board of Directors. Dr. Michael Belkin is a Professor of Ophthalmology at Tel Aviv University in Tel Aviv, Israel, and the Director of the Ophthalmic Technologies Laboratory at the university&#146;s Eye Research Institute at the Sheba Medical Center. &nbsp;He was awarded a master&#146;s degree in natural sciences by Cambridge University, England, and received a doctorate in medicine from the Hebrew University of Jerusalem. Dr. Belkin served previously as Director of Research, Development and Non-Conventional Warfare Medicine in the Israel Defense Forces Medical Corps. He was also the first full-time Director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and the President of the Israel Society of Eye and Vision Research, of which he was one of the founders. </P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>Dr. Belkin is an author of over 250 scientific publications and 20 patents. He is an internationally recognized eye researcher and has received various research awards. He is an entrepreneur and advisor of several ophthalmic companies in the fields of lasers, optics, ophthalmic devices, pharmaceutics and biotechnology. One of his ideas, the ExPRESS miniature glaucoma shunt, is currently used worldwide. Dr. Belkin is an active, long-standing, member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology, the Biomedical Optics Society section of the International Society of Optical Engineering (SPIE), the American Glaucoma Society and many others. &nbsp;He serves as chairman and member of various international and local scientific and professional committees as well as scientific journals&#146; editorial boards. </P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><B><U>About OphthaliX Inc.</U></B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>OphthaliX Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><B><U>About CF101</U></B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug which demonstrated efficacy and an excellent safety profile in Phase 2 clinical studies. CF101 is currently developed for ophthalmic indications, including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify><B>Contact:</B></P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px" align=justify>KCSA Strategic Communications</P>
<P style="margin:0px" align=justify>Jeff Corbin / Phil Carlson</P>
<P style="margin:0px" align=justify>jcorbin@kcsa.com / pcarlson@kcsa.com</P>
<P style="margin:0px" align=justify>212-896-1233</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=justify><I>This release contains forward-looking statements regarding OphthaliX&#146;s future plans and expected performance based on assumptions the Company believes to be reasonable. &nbsp;A number of risks and uncertainties could cause actual results to differ materially from these statements, including, without limitation, the success rate of business development efforts and the timeliness of development activities, and other risk factors described from time to time in the Company&#146;s reports filed with the SEC. &nbsp;In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company&#146;s control. OphthaliX undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.</I></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:12.2px"><BR></P>
<P style="margin-top:0px; margin-bottom:12.2px"><BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 611018AA -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>f8k070213_ex99z1001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 f8k070213_ex99z1001.jpg
M_]C_X``02D9)1@`!`0$`9`!D``#_VP!#``,"`@,"`@,#`P,$`P,$!0@%!00$
M!0H'!P8(#`H,#`L*"PL-#A(0#0X1#@L+$!80$1,4%145#`\7&!84&!(4%13_
MVP!#`0,$!`4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P``1"`!/`5L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]4Z3-&1ZU
M4FN_($LC,!'&I8X(],]^!^/'])6]D!8D;:,YP/IFFM.(UWLP"#J3\N/SKX!_
M:0_X*81^&+W4O#7PXT\S:W;RR6LVKZI$8XK9U;:VR-AEFR#PPX[@<@?"7C?X
M_?$7XEM*WB3QGJ^H1R,2T"73PP?01KA1Q[?A7J4<OJU-9:(M1;/W5F\:>'[6
M4Q3:[IL,HX*/>1AA^!-:-IJ-KJ%M'<6EU!=6\F=DL+AU;!P<$<'D&OYW)`KM
MEP"<\DCJ??U/UKJ/!/Q3\7_#'4FO_"GB+4?#]RZX9K.4JLAR,!D.588_D:[9
M94TKJ8^4_H$#9'-*>HKX/_9/_P""BUMX_P!1T[PE\03;:7KETZVEIJD65@N9
ML#&_/W=V5'8;N.A&/NV,_*"<`^U>-6HSHRY9HAZ$E%)FC-8B%HI,T9]Z`%II
MD4'!(!]Z1CSQ7Y6?M^_&WQWX7^.3Z1X?\<ZSINF-9;Y+.POGB1)1<3)D!<8^
M2-!@<9&3R23O0H2KSY4!^J1D`XR.:-XSG>,=,5_/[KOQ6\;^(',NI^,?$&HE
M%`$=UJD[KC![%R.U?LE^Q3X8D\+_`+,O@2WG:5YY[+[;(TK$L6FD:;G))X\S
M%;XC"/#Q3;`]S'2EIHSCK2UP@%&:YKXA>.++X<^!]>\3ZD&:PT>QEOI1&NYG
M"(6V*.['&![D5\^>%O\`@I-\$?$-O&U]KM]H$K+GRK[2[AB/8E(V`_$U<:<Y
MJ\4!]49%-)P>.3Z5Y[\,OCYX#^,8D/@SQ/9Z_P"5N#K!N1@5V[LJR@C`=?SK
MT#!V^K9[FH<7'1@*7"]3@^E1L_[U?FV@')].G3]1^5?C9^T_^T)\2;/]H/QW
MI^G>/=>LM+T[5I[>SMK*^D@BBC0[``J,/3K@DGD\DFO+O!>O^)/B/\2?#]IK
M>N:[KQGOEDNUFOI9I6@C^=PN6/.U''X@UZRRY\GM'+1HNQ^]$,@D16#!@W((
M/44\5B^"]#C\,^$=#T>)W>+3[&"U5I#\S!(PH)SWXYK:KR;6=B!:**3-`"T4
MF:,T`+112$T`1,Q5Q\Q_W0.O'_UQ3@ZGDGVKX-_X*D_$CQ-X!LOA]'X<\0:E
MH4E^-0,S:;=/`9#&;4KDJ1TWM^=?`;?'[XG*S?\`%Q/%)&3_`,QBXYY/^W7I
M4<!.O#G3T+4;G[UO(5)P0!VR>]+YA&T$X8U^;7_!/OXJ>)8+#QOXU\:>(M=U
M_1K<V^F6J7=[-<@3D&1\(Q()$9!SP!@]R*];\4?'WQ;KM].;6[.BV?F$QQ1(
MA(4'@%B"<^N.Y]*Z,/E&(KS<8;(^5S?B#"9/I5=Y=C[)+X/+@=OQIP;C.1^6
M*^=O@[\>]2UC4%TCQ$#<3/OE34`%C5$6-W;>``/^6;=.QYK\JM6_:-^)EUK6
MHW5M\0_$J1374LD8AU6>-,%SC"[L`8Z<5+RNM&HZ4]&CTLMS&AFM!8B@]#]W
MA(".<CV`IX/'49K\7_V?/VP?'O@3XIZ;?Z[XGUGQ-I5Q(MK<6>H7[RK\SC:5
M+RJJLQ&S+!E7?N(&*_8W1=8LO$.D6FHZ?<QW5E=PI/!<1<K(CCY7!/J#WKAQ
M&&EAY69ZST=C1+8)^88QW]:57&WD@U\R?M=_ME^'_P!GC2YM'MV.I>.+BU,]
MGI\;96(E@B-,1]U6RQ`')"D#!(-?EIJ?[1WQ5O[VXN9?B%XC29Y"SI!J<L48
M;G.U$;:`2<X'ZGD[X?`U,0KHI1;/WD>3;G)``(I^"><U\`?\$N/%/C/QU/X\
MU/Q)XBU?7;&W^S6L/]I7LMP%?!9B-Y('&*^_,9[FN*O3]A-PD2U8&/+$<@<8
M_7BOA'_@HA^UAJOP\N--\">"-9-IKTL;2ZP8$W201.@\F,-SAW)R",$#!KZZ
M^+_Q*LOA3X&U3Q)?20B*SB:1(I9-AG*JTC1IGJY1&('<BOPA\6^+=2\?>*-4
M\2ZQ*9]4U:Y:^FD;D[FY`'H%&`*]#`89U9^T:T14494LLTK_`#M)+*P!!9B)
M`W7C=G;Q@<>_L*N:7HM]KLK1:=:RWDH(+^6,I&I90"TG0`LP`SCG-=S\!/@U
M?_&KQO%I%M;R7-A!&)[[R619C%G.V,NP&]]K`##-@.55MI%?KI\//V4?`?A6
MVM&NO#EE=M!;?9H;&>(26T,>58@H<J[%E#EFW$-G![UZ]?%QP^B*O8_)'Q%^
MS9\2O"NFQZCJ7A>2&VDD6$+;W<,TQ=C\B*B.6+G(X"L*\ZOM.N]'U*:SOX+G
M3[^!C&UO=1-&\3#@J58`@Y!SP._J*_H!O_A[X9U6S2VN_#^F3PQ,'C5[.,B-
MAT91CY2.Q'3%?F?_`,%/?AN?#7C_`$KQ):V$$&GW<4:3WZ&1IIYR'&&!)4;(
M[8]`,A\G)YK+#8]U9\K0<Q\3`,<!9"L\;AAZJPW88'MS_,^IS^W'[%_Q6?XP
M_L[>$]:N;HW.K6\/V#4&<#>)XOE.['<J4;_@5?B.P*A@RB,CC"G.!G(&?QKZ
MZ_9#_:'USX'_``8^(M[IEE;:FVFDZC%9W)81N\DEE#SCTR3QZUOF%#VT$X[H
M&KGZX[@<@,,CK0"3P<5^/7B3_@I5\;-;VPV^IZ1H4>6W26&FG>Q'&T&3=C']
M*ZOX5?\`!2?Q9X$\":B/$;W?CCQ-+<*+9+JWCM+:UB!8LQEC7,I?<HP<8V@<
M')/AO+ZR5R>4_5@/STX]>N:<6!'!!/I7XL>,_P!OKXW>,-4DNE\5CP['NW)8
MZ7$D<2<#Y.06)]26ZYQ@<#K?AM_P4F^+G@S5X9O$D]KXNT:,!;BWN8(X92N2
M2T<D:J6DP``#D<CCO3_LVK&-Q\I^NSXD)&?N\8QWQ7XC_MFWEI>_M(>+&L[R
M6_M7V2QRS8W?O5$Y7Y>,!IG`^@K]@?"WQ6TCQ?\`#"W\:Z?/'-8R::NHO"LR
MNT`,(E,;XZ,JMR.HQ7X=?%:2"3XF^)UM+B:ZM(-1FMX9[@Y>1(SY2LV`!DJ@
MXP,9Q71ED'&I)RZ"BK/4P-+TV76]6T_3H%WRW4L=LB=RSL%'\U_*OZ#/#VGQ
M:-H&F6-M$L$%M;1Q)$/X550`!^5?A!\#-3T;1?C'X/U7Q)=C3]"TS4$O+JY*
M,V%BVR*-HZDLHKZ6^.?_``4N\;^,[][+X>$^$]"C=@+O$;7EW'GA@&5A'Z\<
MUUXZC.O.*AL4T?JV'..!FD5RP!(VGWQ7X;:9^U_\:-*N_M4/Q,UV:7)*I<S"
M6,'<3RKJ1^6*_0']D?\`;@N_B]X>U>U\7V*Q^(-%M'NI9[<+''<*B,WRAB"-
MRI)DXV@J<D9`'E5L#5I+F,[.YVO_``4&\31Z%^S!XPMPRB>\ABBC7.&/^DVZ
ML!Z_*YK\:G4*X0X!`9,X'!`'/Z5]3_MK?M=GX_ZJOAVST>32-,T&\NX$N3>!
MQ?@.@5RI7@;HE8#)^O7/RLZJZ2@']X'.5!&&Z\@BO;P%&5*E[RW+2TU/U$_X
M)>_#BXT;X?:CXIN9)`FK`>3%YI*KMGE4G:3P2(H_P'N<_<W16[<D\U^-_P`+
M_P#@H!\0OA%X$TWPKH6C^'FT[3HO*BDNK61IF!8L-Y5U!QN(''0"OKCX-?M<
M>-_'7[-'CGXD^+X=+LHM,OX+*R_L^"1%_P!9&LA8%FW<RKTQC!KR,3AJOM.=
M[,31^;'Q6UL^(OBGXRU7=_Q^:S>S;NN09WQ^E>G_`+$&D76K_M&^&#:3QVTU
MNZ,6E"$,K.$F5=P.6,+2CV'(P>:\'$KW/[Z08>7]X=IY^;G/XCG\:^@?V1?B
MUX'^!NJZWXS\3VEUJVOVA@&BZ5:QJ?.8Q7(E;<W"##J.>>,U]!5C)4?9Q6MB
MC]IT^X",D]>>/SH656..<_0U^//Q'_X*._&'QO+.FEW]KX0L7<F./2H-TJCI
MAI'W<\'/09KDO!_[;/QE\(ZW#>OXUU+7$&YFL-4F$L$WUXR#[`XKP%EM9KF9
M/*?ML&![TI('I7C?[+7Q]@_:*^%%IXJ6T.FWZ3/9W]EN#>5.H!.#_=*LK#_>
MQVKS/]IW]OGPO\!]1O/#.D0/XD\70)EX81BVM7#*"L\G&TX;H.>:\]49RG[-
M;DO0^K6<<@')'4`]*:LRD]_K@XK\5?'O[=?QK\?74LI\82^'K9SN6TT(?9TC
M7`P%.-YXQR6/.3QQC.\$_MH_&7P/J\>H6WCS5]96.0,]AK4ANHK@=U^;)!/M
MCZUZ']FUN7F*4;G[>AL\9)SWIPQZU^2_Q@_X*3_$+Q1J>AW/@JZ;PM#;V>+V
M(V,<@EN"W\/F*S!0..O-;/PE_P""E_Q6?Q)IFE>(-.T7Q':SW2Q3S?9WMIQ#
MR793&=NY5!)&SH!ZUB\!6C'F9)WO_!772[JZT_X;ZE"BO:V#W\$[9^9))U@,
M0QZ%;><_\`K\YIB`'W$%`"6R.@!7_P"O7V;_`,%*_BC<^)OB-X?\-L-@@T6S
MO[B%2=B3MY['&0#]V51SV[<U\?>'](E\3:]I6EQ(5EO+N*!1NVA6=PH&3[L#
M^%>]@TX4(W-$]#]"OV<_!EWX<_8LLKDV\HDU/6;E[H;2750_E%N/N\PCL1^!
MJ5=/NG90+.9C*-\>Y,K@\Y.#@<>@_+I6S^TU^U%XF_9G\)>"](\,:9HUA)>Z
M?!?7.G7MNT_V<2M.SKD2#Y-R;<]<GKVKY@NOV[/%ES<233>#_"AGR`[I'=J$
M([X%P/3I7H9=C:E*G+2Z;/S3B#A*MFV*6*I5+:6LS[&^&?PZO_%V@>+;J./R
M)8],N[6UN)69$$LMM/'D=CC>N<\`$$<YK\J[ZPNM%O[C3[R/9=VLAAEBR"0Z
M\'H!QD9'U'7K7[4_L9>/->^*GP)TCQ3X@L]/L)[Z:<P6VFQ-%&D(<JO!8\G!
M.[)SGKS7RO\`\%&?V==-TBTC\8Z)8V6G3HQDDECE\J6\)PODA?\`5C:N-OW<
MXVG>2-OE_P!H.KBI\_70^LR3*X91A%A4[]6?GI\LR;2$E4Y!^3((.,CU(XP0
M1CCWK]%/V7/VO=.^$W[&5])X@U$3:KH][=Z;HUJNV24KY*31%U+9*"25ESC&
M%`Z*2/SN/)!!W`\[CGYO?!Z>N.QH!(*]<J=V<]\8[>V.U=E?#QQ%KGO*S1L>
M*O%VL>./%&H>(-<O)+O6;V4S7,S-SYF1D#!P-I"@8QPHZ``5F:?92WUQ#9VT
M1FGE;;'#&,$+ZA<=`WI@`9SM`!):6EQJ5W;6-E;FZO;J18+>VC/[V1SC[H],
M`C=V.2>*_4[]B+]C=/A+:0>*_$44=SXKN8MI=P&6P0Y5HX\<;RO#./5AT``F
MO6AAH6CT'>QVO_!/OX;VG@'X(>9;&4R:I>"YF9SE7=88T?RR0"4WJV"1G`%?
M46*K6&GP:=9P6UM!';6T,8CBAA0(D:``!5`X```&!5L#`KX^I+VLW)F3U/BO
M_@J)KU[IGP6L[&&V6:RU&Z$+S-M)CGW(\>W/3<L<PR/>ORG<#:=N1'CY<G.!
MV_3%?J'_`,%66MG^$6C0-,XNVU6"X5`A*K"B3([$CIS/'BOR\W$L21M8DG:J
MXQST_#I7T^7:4=#1'Z>_\$K/!=JOPJ\2>(GAW75SK30"4XW;8XHR!^!D8^Y.
M>PQ]V`?*.OXU^;O_``2V^-^GZ/::W\.M4N[>UENM12]TM7;!D9XML@Z#O'$!
MR?O@=6&?TAB8/$"""IYR*\'&J2KOFV(;U'D#'O7YM_\`!5GX@P?VOX?\#[6,
M_E6VLG!P0A:\@SZ8SC/UK]!?&7C32/`'A^_US7M0MM,TFRC:6:YN9`BH`,\^
MI/8#FOQ6_:G^/,_[0OQ4EU\6EO96EM;+:VWDS>9)L'+-OVCY<E@%P,9YR<D]
M&7TI3J<_1%Q/&D("AMN[=\P&<XS7T9X<\/)H7[#7BCQ#<VLB3:WXACT^"9AP
M\0:W<@'ZV[G\_2OGF*">>=+>"W::XF<16\(()D8DA0/?G]*^X_VSO#<7PD_9
M(^#/@*)FBFEN6U"ZC9@S&<0%Y')[9>X8XZ#/3@8]W$5/>A30SX7W%MID50@`
M+D<ES7I'P<^!'B#XUS:D-%:&T6SM7NR9(VEFN6CZ)%$H)=LNO4CIUKS>X3;'
MG#D*<!0,@D<<>ISSBOV5_8-\*P:7^S_X<U"6.!KJY2XBC92[*J+.RR;0[-LW
MNA=E7"EB3@9I8VO["FFAWL?FU\<_V4M>^"/A^SUJ\NQ?6$]Q'"T4MD]M<1EP
MWS%&)R`R[2<]Z\/7Y"'VE&QTX('O^5?L9_P48O+"Q_9/\5FZD5);A[6*V4_>
MED\]'V^_RJ[8_P!DU^.>%3*H1M!X(&.,X[?2E@ZTJ\&V@O<^R_V;OCC<^'/V
M1_BSX?E\XFRTN\:VE:9MJ+*\$:JHSC/F7DC%@`3D`G"J!\;2SO=NT\QWS3'S
M7)SDLV2<G\37L^@V":#^R=XHUM;C-WJVN1Z/+:ECN\DB&=74=]SVSK]5->+Q
MQ@*RJPEQD!EX#>X]CU^F/6KI0492:0C?\*>!/$7CA[B31-.GNK.P0RWEXI*P
M6JA6=FD8`A/E0X&>2",9*FNS^(/[.?C'X:>'I]5UC3)HK."Y6W>>2SDBBF7<
M5\R%V"B5&P"K#:"""!CK]J?\$L/#]I>>$O$-U=:(K7,-VM[;ZF[`^8LF8P@'
M^RUJY_X&:[/_`(*FZ_\`V7^S_H^F*PSJ6N0QM#WDCCCD<C\PM<3QDE75)`?E
M-NY0E_,"C"Y((]^A(&/K7T7^QO':6E_XTU2YT^343#IYC<'='"8'#6MPDDBD
M%6VWL;?*<X7-?.F,``A0<<[`%!K]*?\`@E1I,\?AGQ3>SV-O%"7C>UOMI$T@
ME9DD3GC:#:H<=<UV8N2ITFP/SP\3^']4\.W\(UE(X[R\B34MD<R2,4G&X$J#
MP3NSEB"<]ZSM)T^\U_4-.T^Q1Y[V\DBMK:`%=\LCM@8+8!Y(ZYQ7NG[<?B;4
M/$W[1NNP:C\ATMC#;(&!"0M+)+"01ZQ.A(/3..U8?[&_AX>*?VG?AO93)),%
MOTNW`^;9Y4;R<D]LH#CI[5I&I)4?:-=`+4W[%_QF2%6;P4463B-3JMD"!D#D
MF7'J<8[U]3^(M"OO@M_P3I.FI/#;7K7E]%>A&^:5'GFM6`(."RM+&00?X`:_
M0=O#^F3*=VGVK$DD[H5//Y=:^%O^"J=\MOX,\*6EK?K;R+=&.;35!_?1RD.C
M8'96M6Z>M>)'%2Q,XP?<5S\S\?,0"KKDX*YY&>.IZ]S^5>J?!']FSQA\>Y+\
M:$+2TTVU:(W-_?SE(DWEE4;`I9R=C@$<9X->4J,*IR&4)R0,\\'O]:_:C]AW
MP+:^&/V:_`4SV4*ZC/8&=[C8/,99)9)0-W7&9"0.@R<5ZV-Q'U:"MN,_+/XK
M_LQ^*_@[X/TCQ1X@:TMK+4)GA%G.&@O8"K$%I('4'9QD$8R'4]QCR5%+*,N4
M$9R2#C(]O0=Z_1/_`(*P:S:3KX0T?,@U&#,D:1N%,L4V\N.1U#6B=",;N?O"
MOSJ8_:,^6?-`3;\JE,Y/&`>W&1^55A:LJM)2D-,^V/@/\:=1_9E_8SU#Q!90
MJ-8\3ZS=QZ<9(W81[8UA5L@%=P<F0"3;N$<G7`KXPO;N?5;Z:^NYGN[R6=IY
MKJ8EG)+9+$D#J>WO7M'QUO$L/A;\)?#5NNQK+3#<7#M,Q+-,B3QD(3M4C[9,
M,@#(?G.!7ASL)(GW8,;=A]XYZ4J%*,>:HT*QZQ\%?V;/%?QMCGOM)M?LFA6Y
M91J5S`["=UP3%$!PTF&&$'I]ZNZ^,?[#WBWX5^$)/$D-X=>LTN?+DM)-/EM[
MM(PFX3&/YAL^4J6R,$XYP#7Z<_LG>%++PM^SSX"@LE"K/I%O=R;6RIFD022-
MCIDLY)_^L,8/[;5_HUG^SWXE_MF[@LF*F6Q,XR)9XE,PC&/[Z1NF3TW$]A7E
MK'3=;V<>X7Z'XI1@+&``,,N1M]/8Y_K7TK^P+\)_^%G_`!RCF:\GL8M"MTOV
MEMR5+N9XU"$@CAD\WCG(/M7S4(O)79@?+@84$`<>AY'T.2.A/%?HW_P2AT>*
MP\-?$GQ-<$*@GM[02X^ZL<;R-S_P,?G7I8F;C0;"Q\I_MJ>)1XK_`&I?'UXA
M.RVO5TY`0`0($2+V_B0G\:YO]G'PKIGC/XS^%]&UB66WTZZDE0RPQL65C$T<
M7(_Z:O&,^H'K7%^+M8D\0^+-<U:=F>2^O[BZ8L<D^9(S=?QKZ)_X)VZ1/J?[
M1FG3?9$N[2.,1S22JV(>'N$9</UW6@'(_BJIIT\/\@.V_P""H'B33K_XB:-X
M<LDA2\T:)X)F4?O`I@@DB5W/)7$DF!WW9ZU\5N5'G%L0!L^^TX8'^=?1W[??
MB!]>_:/U<3P>3)9QM:2!TVLVV=PC,2`3F$18)[8(XKYTLK5K_4;.SC)DDN[E
M+<1@9.YVVC^8_.C#+EH*_8#]\/@GX,C^'WPG\)>'HT53I^FP0MM4#Y@@W?KG
M\JP_VD[OPGI_PDUNX\97#V^D1Q'YH&59VDQ\HB8_=D(#+NZ`,Q/&2.\UO7K#
MPQH]UJ>J7<5AIUG$9KB>9@J1)UR3^'%?C9^UE^UEKO[0_BN\LXIH;7PG873+
M86]J6)N(UR!(Q('#'YL8_N_W5-?.X:C.O5YO,E1U/%/%LNCS^*M8E\/0S6^@
MR7LSV$-R,2)`78QJ1V(7`YYK)Z].<TNT*KR;BJJ"S%AP"2>/K0RD$!NO;:.O
MX$FOKDK))E'V[_P3A\`>$O&NN7,MZD$FK6DKRNDD1,\@`4*(W8;54JV2%(8[
M)>"`"/U%M(0MO&OE+&%`78@P!CC`'I7X$?"GXE:Q\)OB!HWBK0;ATO\`3;E9
MGBWD1SK@@HW9AY;R8SDC)P037[Q^"_%NG^./"ND:_I=PMSI^IVR7,$B,&4JR
MYQQW'0_0U\OF4)1J*;>A#9NJH08%.I!TI:\HD^?OVTOANGQ*^"NL637<MJZ)
M^Z6WMQ(\DA9/+0G!*)YHC9F7'"`$X)!_%>]LKG3KZ>PNXI(+^V<Q3VLR%'5U
MX.0>1_\`7K^B&9!(""N['&".O]#_`/6K\_?VI/\`@G]?>-_B'/K_`(=U*&RC
MO@\RW$\3R>5.%)*38.=A"DB09(^Z48[37L8#$JF^23T-$?G)I^J7FEW$=S8W
MEU:3QG>DD;F-U^\N?E/'#,..S?E]&:#_`,%$OCGH&GBT/B6UU)>0DM_80O(,
MDG[P`)Z_Q=J\/\4?#;Q/X-!DU;1;^&U=F6"]\@O!<$'!V2K\K$$%<#')((&,
M#F@Q(+*KN`&W(APRA1DDC![5[TXTJUN:*95D>@_%KX]_$#XW7<,OC?Q'/K*P
M/NBL\+':(<#!$*83.`.<$Y[UY_MSN;YQDYRS8W\]L=<GMU+9[5W_`(*^`?Q"
M\>W%JFB^$[^2"=F6.[NH_L]N^Q68X>0@$X!X7<3BOKG]D;]A2:^NU\2^*WM)
M8_(!M4DA>5$=EBDCEB)(64J&D1L@;&'&:RE6I8:-DA;&1^PA^RI:>)M<A\4^
M(4FBU'3KNWN[.V,2O%:H,MMG#<;WSPO&,YY(8+RW_!2[Q7?ZM\;[?1;A,:3I
M<+2V`1H\%9(H8Y>/O?++#(O([9'6OU1\&>#]+\$:!#IND0>1;J?,9V`,DTAQ
MND<\98]_3H,``5^*O[6'CFS^(?Q[\2:KIP;[`1&D0=S(1F,2/@MT!DDD.,@#
M(`X`%>9AJDL3B.9]-A)ZGD.S8Q`.1C:<`\\<\8'6OL[]EK_@H2/@AX$3PGXD
M\/7.M6%JV;"331#"84_B5E&!C.3G&68L223D_(_A#PU<^,?$>DZ+9>6MS?7*
MVB+)PBD]6.!P`#D*`<XK8U;X.>-=$M3+/X7U:XM9`F+RS@:>$;D#J"R+P2"#
M@],UZ]:%*HN293/7_P!K+]L6\_:=ETRTMM(?1?#NF$SV\5S(#*[L?O.!P3MQ
MQR!VP37SDT1\O9%%)++D(D2\EV.<(H_B)..!SQ7>>$?@'\0?'E[:VNF>%=4Q
M<L4CN+^W-K#D#+9DE`5@-IR!DYZ$5]Z?LR_\$]+7P;JND^*_$VIIK>KQNSK;
M^5_HUC(&()C##+2$#J1A<'KP:YYUJ6%IN$!'S/\`M.^$+KX2?`WX1^%+J&2T
MO[N*76+BWN1&'0&*)@K%`&)$LEQC>3MW%1P!CYD++`L@+%BBY<9!7'S<Y^H.
M/K7V[_P44\&^,_B/^T0MOX?\):GKECHNA6D`?3;)[G`E>=\OMY!8_*O')0_C
M\O\`_#/_`,4KM?+C^&_B7>R[1YND3HH)`^8D@#/KSPK#TK3#U8^S4I/<9^I'
M_!.[P7J?@_X!6C:H!B]=+JU5HE5T@EB2<*6`RWSS2$%B3SCH`!XC_P`%>+MT
M3X36FZ01R2:I,`O3>BVNTGZ!V_.OKO\`9:T&/P[\#?"]I#>2ZA"\3RQ3REMQ
MB:1C'][)X38,'L.*^$_^"B6F>.?BA\8H]-T31=2\3Z-H2,R)I5M+.;(S0P;Q
M*`A`W&+<.3QCWKP:'O8OF;TN97U/AISY,2EP5"`EF+97;M.#]<BOUV_8PT6_
M^$?[*KZSK69;:WL7U>VMS&JN+<P+=8.!EF\QY<%@2`P`/``_,5?V?OB:619/
MAYXBM03O:XGTJ:&%4P=SLS+PG`R3R`"1BOV7\#>#+SPM\!QH%A<WMI>P6-Q%
M;2W<:RSQ-ES%E9-P8J-N%8$$``\5Z.858N*C'J7T/Q/^(^H1ZOX^\03Q7<FH
M0"^EBAN9GWM+'&VQ"3Q_"HK1^"WQ5OO@A\3M'\;:=;P7EQI\C+]DN)3&L\;H
M58;NQVLPS79?%C]E?XC?#_Q!>E/"VK:]H;R.]GJVFVLEPCQ$Y7>%#LK`$`Y`
MY![5PC_"7QU'9&YE\&ZY#:-A#<W&GO#"C,RI'^\?"<LV,DXSVKTX3A*GR-]!
MGW=;_P#!5'4O$WB31=)T7P-;::+FZ2.ZN=2O7N?+B^](Z)"H)VJ">?2O(O\`
M@I!XX'BKXL:193PM:ZEI>GPB[,4C[65XHY(P%/'RO/<#.,_-@G@`:O[#7[*W
MB'5O'L/C*]U*TTF'1;M[-K**/[3,S*ZI-$X*[44HTBAP3R3C'&.._:X\%^-_
MBC\==?U70/#&O>*M&@E>TBOK'2I9(P?,,C0L$!^9"Y3+==@(XQCS*<*,:ZY$
M%CY@$$DLD%J0V9W$">N3P/Y"OZ`OACH,/A?X=^%])@79'9:;;P!?]V)17XU_
M![]F3XA:U\2?#L>J>!]>TO2H]3LC=7%_I\EK"BF=%9<R*.2K]O[M?MHB-'&H
M5?E48"^N.F#7/F<XR:460V?DG_P4I^(\GBKX\S>&U<36?AYBB$$'RR\%M(ZX
M]-RMD>H^M?.?POT2#7?B7X7LM0DE-G+J$#7+'EO)$A,K8_W0_P"6>O->C?&S
MX7?$KXB_&#QSXEL_`OB'4[+4=:O&BN;+3I9HF59I(P%=`0<;2IP>"N.U6O@+
M\*_B-X/^-G@G4=1^'NLV^G-K%O87<VM:;+':QQW3BU<ECM^8>>".H+!?>O1I
MRIT\.HWZ&BV.W_X*"?"P^`O%GAG4+1X6TRZLH+.-XWPR>5:6R(7&/EW>1(PY
MY$;YKY/5O+E!3G!^4D=0*_:S]JW]G.U_:`\+PV4MW=6S6\<NR*V"?--M/DR-
MD;BJ'.44JS!R`R_,&_)3Q3\`/'?AG5M3LD\/7VMQ64SQR7ND6[7$&U)'BWX1
M2RAG1Q\P487(X(SG@L3"=/EF]A'M7[.G_!0?Q7\"/!=OX3O=%A\5:+8(T=DL
MMP8)X4ZA=Y4B0`LW7G&.N,5P7[1W[6WBW]I&\MDU9+32=$@W^1I]BS,K?.2I
MD+8R1P"0`#M'7`QP'A'X.^.?'U_:V>A^%-7NVN)XX$GN+<V]OO.=HDDD`4$^
MA(Y*#J37J7Q8_9&\4?#^QT&+1=&U[Q?J-W`LVI365E)+;6TN9$D@4QJP)1X6
MP=QR&!SC&-N3#0J<W4#Y\&Q8P`68@<L_!/;)_&OT;_97U(?#+_@G=\1_%!)6
MXNCJ#1M]W#F)+>,_@]?#&K_!7XA^'M+GU+5O!6OZ=80$))>:A820PKE@HW.X
M&TDDC!]J^S?B-X:\7^#?V#_AY\-].\/76IZKXCM)[F[M;!#-/D745U\JJ27)
M5B#C^&LL7*$^6"?4#\_%&Q?F_'-??W_!+K2[K3&\7^(;J"%-"42>=J$ZMF%[
M=(SA#T*E;F0MD9``]:^08_@#\4-\:GX?>*&E8C).BW`1W)&><#`/S')/85]F
M?LY^']>^&?[#/Q+\0L)O^)EI$PM;9IE!60R7$#MMW$*Y7RNP)(`[##Q<HNER
MQ8'P_P#%#QY=_$WQ]JGB6]D,T]Z8MS-WV1)&,\>B#CV'O74_LR>")O''QQ\*
MVEJ@E^S7]I>3;^D<:W<"DD8)(RXS]:SE_9Q^*40"CX:>+!M)`*Z/*_XY"X.:
M]U_9*^"_CSP=XD\6>);_`$75?#]QH6C3W$=CJ,36LMSOM;HQ@!B#L\V&/D@#
M*DCH#6LIPC2Y$P$_;H_:RUKXK>++[P9H]Q=:5X3TY@MU;,6ADN9@H)$J9^ZK
M%E//)7D5\C^9Y,08$J$49_AR<=!C^$#!^E>H:S\'_B9X]\3^)];L?`^O:RUS
MJ]S)<W-E9&Y02LQD:,NG\0W@\GD8-=_^SY^R'XJ\<_$RPTOQ/H5YIEC`XDFL
M[I#%.T:D'#H2#$I&TY.,ADQG>-LPG2H4O=DK@=!^PW^SC:?$_P`<V>K^)=/6
M^TZT5IK;361FCE8])Y2?^6?0JISGDMU0/Y3^U!X"@^'7QN\1:!';#3C',&9(
M;7RK7>8U=O(R^YEV.K9(&2YP-N`/VV\,^$-,\,6T4&G6%O9JD$=OFVB$?[M`
M=B#'.T98@9X)/<DGXO\`^"D?P/3Q%H4?BNVGF345?;%\KNNX1X,?WU2,$*6Y
M!9F`&]5!4^?1QS=?7X17/S#9L[L`J3G"]#FOT?\`^"6GQ.\1:II>L^#;B87/
MA[2'22T7!+PF;S&P#V4&%_EZ_O5/0<?"GA_X)_$+Q1:O<Z'X)US6;6)C"\^F
MV;W$<;@`X+(.JAAP,DAAZFOOS_@F3\'-;\)6.O>(]8BN-)>XN)]/?2YVP^^(
MQ#=)'_"Z'SDZ<9;UKMQLZ<J#5TQV/OJ/.T9ZT^F1DE1D8I]?)HR$*@U$85=]
MY7Y\8S_GZU-13\P/.O$'P%\"^(WTIKOP]&ATNY%W9+9RR6R02A@P;9&RJ?F4
M,05())R#DYJW/P!\,ZE!J-O?-?7=IJ$4D-S;R3A5='4JRY0!EX/4$$>M>G8I
M,`<8ZU:J36T@NSD/!_PH\*>!=(LM,T31X[:SLW,MO')))/Y3GJRM(S$'WSFN
MK\E=NW;\O3':I`-HQ2]C4MMZMAJ<]XXUM_"_@S7=6A1I9=.L)[N.)%R6*1LP
M4>Y(K\#_`!W<V%YXT\0OI<)M]*;4I_LD)9F*0K(PB&7)8X4`98DGJ3DYK]ZO
MB%I^I:IX2U"TTGB_F5(XRP5EP77.0S`'C/6OS6E_X)<>-YY7D/B!F:1MY?['
M`3EN3_R\CO[5ZV`K4Z+;FS1'C'[#6BIKW[5W@".;(6WN9;L*N004@D/!ZKSZ
M8Z5^P_B7X3^$_%]I/:ZIHEO-!<2^=.L):#SI-H7<YC*EC@``MG&.*^/_`-DS
M]@_Q%\"_C/8^,-6U2"]M+:SN(1"\:12([J%#($>0,,$YRR_0X%?=T9+*#ZUA
MC:ZG5O39#;N<AX8^$_A/PC8)9:7HL4-M&XD1)7>;:P4KD%R2#@GGWKJS;ID$
M(`1TQQZ<?H*FR*!7GN3>K8KF//X3TBXO;F].G6ZWMRJ+/<H@264)NV!G')V[
MFQGIGC%.3POID3Y6VP?4.W/!'///4UK`YHI\SM:X796L=/M],L8;.T@2VMH4
M$<<,0PJ*.@%47\+:1)>W5W_9UO'=W6TW$\2".2;`PN]EP6P.F<]!Z"M<]*AF
MD:-EP0`>.1DY[4E?H!EOX1TEXI(WLEECD4JZ2,SJP/!!!."".U:PB&!\HXZ>
MW^%,:7#HJMEF!*J>_?K1(YB4,W&3@Y_I@4/WM&QW,[5/">DZU:2VUW9))!(,
M.J$QEA]5P:Q8OA'X/33FTZ3P_:7>GOC?:WJFYB?!##<DA8'!4$9!P1Q78IG:
M-W6E/K34FMF*[*T=G#!%'$D2QQH`%1!@*!Z8K,C\&Z-!]I$&FVUL+F9KBX%N
MGE":5A@R/MQN8\<GFM22<1AGW813R<?I_*IDR5!)SWHYFM;AJ9L/AO380`MH
MI`=9`');#*<@C.<$'^5:+(K=L\8Q3STJO--Y3J6;`;A0!W/3^1I7;W8&;'X.
MT6"U%M!IEO;6ZLSK#;IY:!F8LS`+@9+$DGN2<TK^$M(E$:RV$<Z1R),B39=%
MD5@R,%.0&5E!!Z@@<UL(3M&:=3YGW#4B:('HN.<\<5@:OX`\/ZZU\U[I4#RW
MT8ANID!CEF0=%9U(8@=N>.@Q7244)M;#N<!X,^!O@CX?V\MOH6@QVEO)*L[P
MO/+,C.OW6(D=@6'8]L#T%=;?:%9:EM^T0>8%&T`,5![]`1WK0R/2EH<I/=A<
MP;[P3H>JZ?-I]_I5OJ%A-@R6EZGGPR8.061\@G/J*E3PCHL::>J:5:1C3D:.
MSV0JIME(VD1D?<!&!QCI6U2&CF?<5V9*^%].5MPMSGU\Q^?KSS56+P'X<@\-
MMX>30-,30F&TZ:EH@MB,[C^[V[?O'/3KS709%+0V^K"[,UM"LI'+M`"3U^9O
MP[U!_P`(II#R7#MIEM(]Q`+69Y(@QEA!8^6Q/)7YW^4\?,>,&MC-+0Y/JPNS
M!T?P/H'AVWGM](T:RTFWG<S2Q6$"VZ22$`%F"``D@`9(J]9:+8V-[<W=O9Q0
MW=SM$]PL8$DH4$*&;J0`3@=!GC%:%%*X:B$#&*JWVG6VIVL]K=V\5U:W"-%-
M!,N])$8$,K`\$$$@@C!!-6Z*`.>\/>`_#WA&S>TT+1+'1;623SGATZW6!'DP
M`78(!EB``2>3C&:OZ3H.G:(DBZ?86]BLLKSR"WB"!Y';<[D`<LS98GJ223R<
2UH@YH--R;T;"[`#%+112`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
